| |
|
Policy Matters: March 2017
|
|
|
Announcements and Features
|
|
New Series Features Duke-Margolis Expertise
To enhance collaboration and help faculty and staff get to know each other across locations, we are launching a new web series -- Humans of Duke-Margolis.
Volunteers are needed, please
email Ellen de Graffenreid if you're willing to be a "Humans" subject!
|
|
|
Sentinel Initiative Marks Progress
On February 2, 2017, the Duke-Margolis Center for Health Policy hosted the 9th Annual Sentinel Initiative Public Workshop. For almost a decade, this workshop has provided a forum for the public, researchers, and key stakeholders to learn about the Sentinel Initiative’s recent achievements and next steps in its development. In 2008, the Food and Drug Administration (FDA) launched the Sentinel Initiative in response to legislative authority to create a national electronic system that actively monitors the safety of medical products such as drugs. The Sentinel Initiative has made it possible for FDA to securely access diverse healthcare data sources, including electronic health records and claims databases, to rapidly investigate potential safety concerns.
Dr. Greg Daniel, Deputy Director of Duke-Margolis, who serves as Principal Investigator for the cooperative agreement between Duke-Margolis and the FDA, and
Dr. Mark McClellan served as moderators at the public workshop.
Read the full story
|
|
Meet Isha Sharma
Isha Sharma is a Senior Research Assistant in medical devices and evidence generation at the Duke-Margolis Center for Health Policy. Prior to Duke-Margolis, Isha worked at Northwestern University’s Feinberg School of Medicine as a Research Assistant. At Northwestern, Isha conducted long-term primary and secondary research using surgical EHR data to stimulate the development of a novel cancer diagnostic and therapeutic tool. Isha graduated from Case Western Reserve University in 2014 with degrees in Biology, Medical Anthropology, and Global Health.
|
|
|
June 14-15 Duke-Margolis Center for Health Policy Washington, DC
|
|
|
Strategies for Assessing Delivery System Innovations
How can healthcare organizations determine whether innovations really improve service delivery, patient experience, clinical outcomes, or costs?
At a briefing on March 7 in Washington, DC, Mark McClellan, Director of Duke-Margolis and Elizabeth McGlynn, Vice President for Research at Kaiser Permanente, discussed their article in the March 2017 issue of Health Affairs.
|
|
Children Insured Under the Affordable Care Act May Lack Access to Pediatric Specialists
In a paper published online on March 1 in Pediatrics, Charlene A. Wong, MD, MSHP, Kristin Kan, MD, MPH, MSc, and colleagues collected and analyzed data from the ACA silver-level health insurance plans and found that pediatric specialists are not well-represented in “narrow” networks – those with no or limited numbers of physicians from a given geographic area. In addition, the proportion of insurance networks including no specialists was significantly higher for all pediatric specialties than for adult specialties (excluding nephrology).
Read More
|
US Investment in Global Health R&D Saves Lives, Boosts Economy
New report examines opportunities to strengthen US government role in developing global health technologies
U.S. government investment in developing vaccines, drugs, and other tools to combat neglected diseases and conditions has reached its lowest level since 2007, excluding emergency funds provided to combat the Ebola outbreak.
Reversing this decline in US investment and advancing policy solutions to build new partnerships, leverage expertise, and encourage investment from all sectors, will save lives and increase economic opportunity in low- and middle-income countries, while also creating jobs and boosting the U.S. economy, says a team from the Duke-Margolis Center for Health Policy, Duke Global Health Institute (DGHI) and DGHI’s Center for Policy Impact in Global Health.
|
|
|
JAMA Viewpoints: Two-for Tuesday
February 28 was a double hit for Duke-Margolis with two Viewpoints published in JAMA.
Regina Herzlinger of Harvard Business School,
Barak Richman of Duke University’s School of Law, Fuqua School of Business, and the Duke-Margolis Center for Health Policy, and Richard Boxer of the David Geffen School of Medicine at UCLA argue that Switzerland, Singapore and Germany have achieved universal insurance coverage, effective pooling of risk across populations, and an affordable cost through an individual mandate.
|
|
|
Duke University Team Proposes Principles for Advancing Value Assessment
In an article published in the journal Value in Health, a team from Duke-Margolis, Duke Clinical Research Institute and several external organizations argues that stakeholder input and buy-in are important to ensure the adoption and sustainability of value assessment in the U.S. The researchers convened a small group of stakeholders representing patient advocacy organizations, drug manufacturers, payers, and academia to discuss factors that hamper uptake or result in misinterpretation.
The team was led by Corinna Sorenson of DCRI and Mark McClellan of the Duke-Margolis Center for Health Policy and included Gabriela Lavezzari and Gregory Daniel from Duke-Margolis, Gillian Sanders from DCRI, Edmund Pezalla from Enlightenment Bioconsult, LLC, Marc Boutin from the National Health Council and Randy Burkholder from the Pharmaceutical Research and Manufacturers of America.
|
|
|
Donald H. Taylor, Jr, PhD, MPP was quoted in the New York Times' analysis of Healthcare Proposal.
Dr. Taylor has also been elected chair of the Duke Academic Council for 2017-2019.
McClellan, Califf Talk About the Future of Health Care Dr. Mark McClellan and Dr. Robert Califf spoke at the CED Life Sciences Conference in Raleigh on March 1. Read more about their remarks in Exome.
Dr. McClellan also spoke with NPR's Audie Cornish on an All Things Considered segment on the President's critique of the drug approval process and was extensively quoted in Healthcare IT News: Healthcare IT Needs More Private Development.
Dr. Greg Daniel provided an overview of the 21st Century Cures Act and its implications as part of the NIH Collaboratory Grand Rounds on January 23 and was an invited speaker at the BIO CEO and Investor Conference in New York on February 14, where he presented ideas for Designing Clinical Trials in a 21st Century Cures Paradigm. He recently spent a week in Singapore working on potential collaborations, and was an invited speaker on March 13 at the 7th International Conference on Global Health where his talk focused on Antibiotics Stewardship and Innovation.
Congratulations to Elizabeth Richardson whose Op Ed, "Federal right-to-try legislation undermines patient protection and drug testing" was featured by STAT in its First Opinion column. The link was tweeted out by the internationally-known bioethicist Art Caplan!
|
|
|
Interesting Project? Funding Opportunities? News and Events? Awards and Honors?
Policy Impact? Op Eds?
We're looking for ways to highlight your accomplishments and share information.
|
|
|
|
|
|
|
|
